<DOC>
	<DOCNO>NCT02201576</DOCNO>
	<brief_summary>The purpose study assess efficacy bortezomib , association steroid , plasma exchange , polyclonal intravenous immunoglobulin , treatment chronic antibody mediate rejection due donor specific anti-HLA antibody , kidney transplant recipient</brief_summary>
	<brief_title>Bortezomib Rejection Kidney Transplants</brief_title>
	<detailed_description>Chronic active antibody-mediated rejection ( AMR ) consider main cause late allograft loss kidney transplant recipient . It due occurrence de novo donor-specific anti-HLA antibody ( DSA ) , i.e . antibody synthetized recipient transplantation transplant . There currently efficient treatment . The purpose study determine efficacy bortezomib , proteasome inhibitor , treatment chronic active antibody-mediated rejection , association steroid , plasma exchange , polyclonal intravenous immunoglobulin . Patients recipient first second kidney transplant 6 month . They display de novo DSA i.e . DSA detect last annual systematic screening , transplantation . They display sign chronic active AMR kidney biopsy i.e . glomerulitis ( g ) + peritubular capillaritis ( ptc ) Banff score g+ptc &gt; 2 , without severe chronic glomerulopathy ( Banff score cg &lt; 3 ) . Kidney biopsy may perform three circumstance : 1. detection de novo DSA annual screening , 2. proteinuria ( &gt; 0.5 g/24h ) slow graft dysfunction ( increase &gt; 20 % serum creatinine three-month lap ) 3. protocol biopsy Primary endpoint combine endpoint one year inclusion , consist stabilization histological lesion new kidney biopsy ( delta g+ptc ≤1 delta cg &lt; 1 ) decrease DSA mean fluorescence intensity &gt; 50 % .</detailed_description>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>recipient first second kidney transplant 3 month age 18 year de novo donor specific antibody ( DSA ) , i.e . antibody detect transplantation last systematic posttransplant screening ( realize every centre 3 month 6 month , 12 month first year transplantation , annually ) . In case serum miss annual screen year precede inclusion , maximal deadline two year last negative research DSA inclusion study accept . histological lesion chronic active antibodymediated rejection ( glomerulitis + peritubular capillaritis banff score chronic glomerulopathy ( g+ptc ≥ 2 ) graft biopsy perform renal function deterioration , proteinuria , detection de novo DSA , systematic biopsy write informed consent Women child bear age must negative pregnancy test day inclusion use contraceptive method study Men old enough procreate include arm Bortezomib use Bortezomib treatment 3 month affiliate social security health insurance patient preform DSA recipient 3rd 4th kidney transplant recipient transplant combine another renal organ patient history antibodymediated rejection current transplantation estimate GFR 30 ml/min/1,73m2 severe transplant glomerulopathy ( cg score = 3 ) severe peripheral neuropathy , thrombopenia &lt; 100 000 mm3 , neutropenia &lt; 1000 mm3 and/or uncontrolled evolutionary infection chronic active hepatitis B ( positive HBs antigen HBV DNA ) , positive chronic hepatitis C and/or know HIV infection allergy bore bortezomib one excipient hepatic failure , abnormal liver test ( bilirubin &gt; 3N , transaminase &gt; 3n ) , infiltrative pneumopathy , pericarditis risk nonadherence treatment protocol inclusion another clinical therapeutic trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Chronic antibody-mediated rejection ,</keyword>
	<keyword>transplant rejection , kidney transplantation ,</keyword>
	<keyword>proteasome inhibitor ,</keyword>
	<keyword>anti-HLA antibody ,</keyword>
	<keyword>immunosuppressive agent</keyword>
</DOC>